Literature DB >> 12181462

Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.

J del Amo1, J del Romero, A Barrasa, S Pérez-Hoyos, C Rodríguez, M Díez, S García, V Soriano, J Castilla.   

Abstract

OBJECTIVE: To study HIV progression from seroconversion over a 15 year period and measure the population effectiveness of highly active antiretroviral therapy (HAART).
METHODS: A cohort study of people with well documented dates of seroconversion. Cumulative risk of AIDS and death were calculated by extended Kaplan-Meier allowing for late entry. Cox proportional hazards models were used to study variables associated with HIV progression. To assess the impact of HAART, calendar time was divided in three periods; before 1992, 1992-6, and 1997-9.
RESULTS: From January 1985 to May 2000, 226 seroconverters were identified. The median seroconversion interval was 11 months, median seroconversion date was March 1993. 202 (89%) were men, 76% of whom were homo/bisexual. A 66% reduction in progression to AIDS was observed in 1997-9 compared to 1992-96 (HR 0.34 95% CI: 0.16 to 0.70). People with primary education appeared to have faster progression to AIDS compared to those with university studies (HR 2.69 95%CI: 1.17 to 6.16). An 82% reduction in mortality from HIV seroconversion was observed in 1997-9 (HR 0.18 95% CI: 0.05 to 0.68) compared to 1992-6. Progression to death for people with primary education was twice as fast as for those with university education (p 0.0007). People without confirmation of an HIV negative test had faster progression (HR 4.47 95% CI: 1.18 to 16.92).
CONCLUSIONS: The reduction in progression to AIDS and death from seroconversion from 1992-6 to 1997-9 in Madrid is likely to be attributable to HAART. HIV progression was faster in subjects with primary education; better educational level may be associated with better adherence to medication.

Entities:  

Mesh:

Year:  2002        PMID: 12181462      PMCID: PMC1744500          DOI: 10.1136/sti.78.4.255

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  22 in total

1.  The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters.

Authors:  K Porter; A M Johnson; A N Phillips; J H Darbyshire
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS).

Authors:  M Dorrucci; M Balducci; P Pezzotti; A Sinicco; F Alberici; G Rezza
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

3.  Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.

Authors:  A N Phillips; S Grabar; J M Tassie; D Costagliola; J D Lundgren; M Egger
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

4.  Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.

Authors:  V Gordillo; J del Amo; V Soriano; J González-Lahoz
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

5.  [AIDS-free time and survival of an injecting drug users HIV seroconvertors cohort].

Authors:  S Pérez-Hoyos; M Aviñó; I Hernández; J González; I Ruiz
Journal:  Gac Sanit       Date:  1999 Sep-Oct       Impact factor: 2.139

6.  Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe?

Authors:  M Prins; R P Brettle; J R Robertson; I Hernández Aguado; B Broers; N Carré; D J Goldberg; R Zangerle; R A Coutinho; A van den Hoek
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Impact of human immunodeficiency virus infection on mortality among young men and women in Spain.

Authors:  J Castilla; M V Martínez de Aragón; A Gutiérrez; A Llácer; M J Belza; C Ruiz; J Pérez de la Paz; I Noguer
Journal:  Int J Epidemiol       Date:  1997-12       Impact factor: 7.196

9.  Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study.

Authors:  P Pezzotti; N Galai; D Vlahov; G Rezza; C M Lyles; J Astemborski
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-03-01

10.  Impact of socioeconomic status on survival with AIDS.

Authors:  M H Katz; L Hsu; M Lingo; G Woelffer; S K Schwarcz
Journal:  Am J Epidemiol       Date:  1998-08-01       Impact factor: 4.897

View more
  5 in total

1.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001.

Authors:  Denis Nash; Monica Katyal; Sarita Shah
Journal:  J Urban Health       Date:  2005-10-19       Impact factor: 3.671

3.  Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

Authors:  Manuela García de la Hera; Inmaculada Ferreros; Julia del Amo; Patricia García de Olalla; Santiago Pérez Hoyos; Roberto Muga; Jorge del Romero; Rafael Guerrero; Ildefonso Hernández-Aguado
Journal:  J Epidemiol Community Health       Date:  2004-11       Impact factor: 3.710

Review 4.  Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.

Authors:  Paige Etter; Raphael Landovitz; Sengeziwe Sibeko; Magdalena E Sobieszczyk; Sharon A Riddler; Carissa Karg; Athe Tsibris; Jeffrey Schouten
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

5.  Factors associated with improvement in disability-adjusted life years in patients with HIV/AIDS.

Authors:  Clara Bermudez-Tamayo; Jose Jesus Martin Martin; Isabel Ruiz-Pérez; Antonio Olry de Labry Lima
Journal:  BMC Public Health       Date:  2008-10-21       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.